Mashable, February 16, 2019 By Michael E. Davenport As the first step toward a more efficient way of managing diabetes, researchers at MIT and MIT Sloan Kettering are working on an innovative diabetes therapy that can be administered to people of all ages, in all geographic locations.
A recent collaboration between the University of Massachusetts-Amherst and MIT and the Massachusetts Diabetes Association (MDA) is the first of its kind in the United States.
The new device, called the VESicles, can deliver insulin injections and other interventions to the same people at the same time.
“It’s very important that people understand what they’re getting, because they’re the ones who will be most affected by the device,” said Dr. Robert D. Warshaw, associate professor of pediatrics and professor of medicine at the University at Buffalo and associate director of the New York City-based National Institute of Diabetes and Digestive and Kidney Diseases.
Deeper insight from the device The device, which will be used in clinical trials at MIT, MDA, and the University School of Medicine at Boston, is the culmination of years of research into the potential of a diabetes intervention to improve the quality of life of people with diabetes.
“The VESicle was born out of the desire to make an intervention that could be administered in the same manner that patients with diabetes are already getting care,” Warshaws said.
According to the researchers, the device, developed by MDA’s Center for Diabetes, Metabolism and Health, is based on the same principles that were used to develop the first-generation insulin-delivery device called the Nexcel.
Nexcel, created by Harvard University in the 1970s, was the first to deliver insulin to a person of all races and ages.
In the years that followed, researchers found that the delivery of insulin to patients of all colors, ages, and income levels was optimal.
It is important to note that the Vesicles is not a replacement for insulin, but instead a targeted intervention that provides the patient with a unique, personalized, and cost-effective treatment, said WarshAW.
The Vesicle uses a new approach called biofeedback, which allows a person to monitor and analyze the effects of the insulin on his or her body.
As part of the study, Warshews will use the device during the clinical trial at MDA and at the Massachusetts Institute of Technology (MIT).
“I believe that this device could be a tool to help us in the future,” he said.
According to Warshavys, the Vresicles will help diabetes patients manage their diabetes with more efficiency, better adherence, and greater access to care.
As a patient of diabetes, I would expect to see a decrease in costs associated with care, said J.J. Schafer, associate director for medical affairs at MDC.
If patients are not being fully supported by their physicians, there are things that we can do to improve their quality of care,” said Schafer.
MDA’s Dr. Daniel R. Lipski, assistant director of diabetes and obesity at the MIT Sloan School of Management, said the Valsicles has a number of potential applications.
First, the company is developing the device to help people with chronic kidney disease manage chronic kidney failure, which is a progressive disease that often leads to renal failure.
A clinical trial with diabetes patients enrolled in a Phase III trial is underway.
This trial will test the Vésicles treatment on people with Type 1 diabetes and those with chronic renal failure who do not respond to existing therapies.
Second, Warsaw said, the study is looking at the potential for a treatment to improve patients’ overall quality of health.
When you look at a patient with Type 2 diabetes, for example, the blood glucose level can be very low and the insulin levels are high, so a drug can help.
Third, if the patients are able to use this device to get the treatment as a treatment option, they will see a significant reduction in the amount of time they need to get diabetes medication.
And lastly, the researchers hope to see that people with type 2 diabetes can get the insulin injections in a manner that is efficient for them.
Currently, the only way to deliver this therapy to people with high blood pressure is through a syringe, but the Vsicles can deliver it with a remote-controlled device that is implanted into the arm.
While the device is not the first diabetes treatment to deliver the treatment remotely, the team hopes that with the help of the public and the technology community, the next generation of diabetes treatments can deliver this type of treatment in a way that is more efficient and convenient for people with the disease.